Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Hydrochloride Liposome (HE071) in Relapsing Multiple Sclerosis
CTR20221913Phase 2Terminated
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Aug 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome in multiple sclerosis (MS), sponsored by CSPC Zhongnuo Pharmaceutical. Started Aug 2022; status: terminated.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on CTR20221913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221913.